BYSI vs. MBIO, ACIU, HRTX, AMLX, NGNE, ATAI, DMAC, URGN, ELDN, and LFCR
Should you be buying BeyondSpring stock or one of its competitors? The main competitors of BeyondSpring include Mustang Bio (MBIO), AC Immune (ACIU), Heron Therapeutics (HRTX), Amylyx Pharmaceuticals (AMLX), Neurogene (NGNE), Atai Life Sciences (ATAI), DiaMedica Therapeutics (DMAC), UroGen Pharma (URGN), Eledon Pharmaceuticals (ELDN), and Lifecore Biomedical (LFCR). These companies are all part of the "pharmaceutical products" industry.
BeyondSpring vs.
Mustang Bio (NASDAQ:MBIO) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, community ranking, profitability, risk, analyst recommendations, dividends and media sentiment.
BeyondSpring has higher revenue and earnings than Mustang Bio.
BeyondSpring received 16 more outperform votes than Mustang Bio when rated by MarketBeat users. Likewise, 66.79% of users gave BeyondSpring an outperform vote while only 64.26% of users gave Mustang Bio an outperform vote.
Mustang Bio currently has a consensus price target of $100.00, indicating a potential upside of 2,303.85%. Given Mustang Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Mustang Bio is more favorable than BeyondSpring.
Mustang Bio has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Comparatively, BeyondSpring has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500.
In the previous week, Mustang Bio had 2 more articles in the media than BeyondSpring. MarketBeat recorded 6 mentions for Mustang Bio and 4 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 0.59 beat Mustang Bio's score of 0.55 indicating that BeyondSpring is being referred to more favorably in the news media.
10.0% of Mustang Bio shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 0.6% of Mustang Bio shares are held by insiders. Comparatively, 29.3% of BeyondSpring shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
BeyondSpring beats Mustang Bio on 8 of the 13 factors compared between the two stocks.
Get BeyondSpring News Delivered to You Automatically
Sign up to receive the latest news and ratings for BYSI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BeyondSpring Competitors List
Related Companies and Tools
This page (NASDAQ:BYSI) was last updated on 1/29/2025 by MarketBeat.com Staff
Free BYSI Stock Alerts